Table 3.
Univariable and multivariable associations of serum MIF in SSc and SLE
| Serum MIF levels (pg mL−1) derived from univariable linear regression analyses | Serum MIF levels (pg mL−1) derived from multivariable linear regression analyses | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Exposures | RC | 95% CI | P ‐value | RC | 95% CI | P ‐value | ||||
| Age | 1.01 | 1, 1.02 | <0.01 | 0.99 | (0.98, 1) | 0.1 | ||||
| GM | 95% CI | Ratio of GM | 95% CI | P ‐value | GM | 95% CI | Ratio of GM | 95% CI | P ‐value | |
| Disease | ||||||||||
| HC | 125 | 73, 214 | 1.00 | 106 | 62, 179 | 1.00 | ||||
| SSc | 808 | 638, 1024 | 6.5 | 3.5, 11.8 | <0.01 | 889 | 704, 1123 | 8.4 | 4.7, 15.1 | <0.01 |
| SLE | 255 | 200, 325 | 2 | 1.1, 3.8 | 0.02* | 252 | 201, 316 | 2.4 | 1.3, 4.3 | <0.01** |
| Angiotensin II receptor blockers | ||||||||||
| No | 387 | 316, 474 | 1.00 | ‐ | ‐ | ‐ | ||||
| Yes | 391 | 242, 633 | 1.01 | 0.6, 1.7 | 0.97 | ‐ | ‐ | ‐ | ‐ | ‐ |
| Beta blockers | ||||||||||
| No | 379 | 323, 445 | 1.00 | ‐ | ‐ | ‐ | ||||
| Yes | 522 | 262, 1040 | 1.4 | 0.7, 2.8 | 0.37 | ‐ | ‐ | ‐ | ‐ | ‐ |
| Angiotensin II receptor blockers and/or beta blockers | ||||||||||
| No | 379 | 319, 449 | 1.00 | ‐ | ‐ | ‐ | ||||
| Yes | 422 | 259, 686 | 1.1 | 0.7, 1.8 | 0.67 | ‐ | ‐ | ‐ | ‐ | ‐ |
| Gender | ||||||||||
| Males | 473 | 292, 768 | 1.00 | 492 | 336, 720 | 1.00 | ||||
| Females | 312 | 257, 378 | 0.7 | 0.4, 1.1 | 0.09 | 310 | 271, 354 | 0.6 | 0.4, 0.9 | 0.02 |
| Ethnicity | ||||||||||
| Other | 321 | 259, 398 | 1.00 | ‐ | ‐ | ‐ | ||||
| Caucasians | 334 | 271, 413 | 1.04 | 0.8, 1.4 | 0.8 | ‐ | ‐ | ‐ | ‐ | ‐ |
95% CI, 95% confidence interval; GM, geometric mean; MIF, macrophage migration inhibitory factor; RC, regression coefficient.
*
Ratio GM (95% CI) SSc vs SLE: 3.17 (2.37, 4.24); P < 0.01.
**
Ratio GM (95% CI) SSc vs SLE: 3.53 (2.6, 4.8); P < 0.01.